期刊文献+

不同剂量氮斯汀及联合西咪替丁治疗慢性荨麻疹疗效观察 被引量:7

Different dosages of azelastine and in combination of cimetidine in the treatment of chronic urticaria
下载PDF
导出
摘要 目的:对比不同剂量氮斯汀及联合西咪替丁治疗慢性荨麻疹的疗效及不良反应。方法:采用随机入组开放观察同样疗程不同剂量氮斯汀(A、B两组)及联合西咪替丁(B+C组)治疗慢性荨麻疹的疗效及不良反应。A组患者采用氮斯汀4mg/d治疗;B组患者采用氮斯汀2mg/d治疗;B+C组患者采用氮斯汀2mg/d联合西咪替丁400mg/d治疗。3组患者均在28d时观察疗效及不良反应。结果:A组显效27例(81.8%),良效4例(12.1%),微效2例(6.1%);B组显效21例(61.8%),良效6例(17.6%),微效7例(2.06%);B+C组显效26例(78.8%),良效3例(9.1%),微效4例(12.1%)。A组出现口干1例,困倦2例;B组出现口干3例,头昏、困倦1例;B+C组出现困倦3例,口干1例。均不影响疗效。结论:A组及B+C组患者的疗效相似,且高于B组,差异有统计学意义(P<0.05)。 Objective: To evaluate effects and side effects in different dosages of azelastine and in combination with cimeti dine for treatment of chronic urticaria. Methods: By open randomized grouping to evaluate the effects and side effects of 4 mg/d (A), 2 mg/d (B) and 2 mg/d azelastine combined with 400 mg/d cimetidine (B+C) P.O. for 28 d in treating chronic urticaria in each group. Results: In group A, there were 27/33 (81.8%) marked improved, while in group B, there were 21134 (61.8%) marked improved, χ^2=3.31, P〈 0.05. In group B+C, there were 26/33 (78.8%) marked improved, no significant difference with group A. There were no difference in side effects of these 3 groups. Conclusion: There is no difference in side effects of A, B and B+C groups, hut the effects in group A and group B are different (P〈 0.05).
出处 《临床皮肤科杂志》 CAS CSCD 北大核心 2008年第3期194-196,共3页 Journal of Clinical Dermatology
关键词 荨麻疹 慢性 氮[艹卓]斯汀 西咪替丁 urticaria, chronic azelastine cimetidine
  • 相关文献

参考文献9

  • 1国家药典委员会.《中华人民共和国药典:临床用药须知》化学药和生物制品类[M].北京:人民卫生出版社,2005:741-742.
  • 2Casale TB. The interaction of azelastine with human lung histamine HI, beta, and muscarinic receptor-binding sites[J]. J Allergy Clin Immunol, 1989, 83(4): 771-776.
  • 3Chand N, Pillar J, Diamantis W, et al. Inhibition of IgE-mediated allergic histamine release from rat peritoneal mast cells by azelastine and selected antiallergic drugs [J]. Agents Actions, 1985, 16(5): 318-322.
  • 4Chand N, Pillar J, Diamantis W, et al. Effect of azelastine on activation and release stages of allergic histamine secretion in rabbit basophils[J]. Res Commun Chem Pathol Pharmacol, 1991, 72(1): 121-124.
  • 5Fields DA, Pillar J, Diamantis W, et al. Inhibition by azelastine of nonallergic histamine release from rat peritoneal mast cells[J]. J Allergy Clin Immunol, 1984, 73(3): 400-403.
  • 6Tamaoki J, Yamawaki I, Tagaya E, et al. Effect of azelastine on platelet-activating factor-induced mierovascular leak age in rat airways[J]. Am J Physiol, 1999, 276(2 Pt 1): L351-L357.
  • 7Kempuraj D, Huang M, Kandere-Grzybowska K, et al. Azelastine inhibits secretion of IL-6, TNF-alpha and IL-8 as well as NFkappaB activation and intracellular calcium ion levels in normal human mast cells[J]. Int Arch Allergy Immunol, 2003, 132(3): 231-239.
  • 8Kusters S, Schuligoi R, Huttenbrink KB, et al. Effects of antihistamines on leukotriene and cytokine release from dispersed nasal polyp cells[J]. Arzneimittelforschung, 2002, 52(2): 97-102.
  • 9Kempuraj D, Huang M, Kandere K, et al. Azelastine is more potent than olopatadine n inhibiting interleukin-6 and tryptase release from human umbilical cord blood-derived cultured mast cells[J]. Ann Allergy Asthma Immunol, 2002, 88(5): 501-506.

同被引文献27

引证文献7

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部